DOSING & ADMINISTRATION
A B-cell treatment designed with your patients in mind1
What makes KESIMPTA® (ofatumumab) different?
It's the Only SC delivered B-cell RMS treatment3
Your patients treat themselves at home in just
1 MINUTE A MONTH* when they're ready to administer
*As per stability technical specification data, when the patient is ready to inject, it typically takes less than 1 minute a month to administer. Once-monthly dosing begins after the initial dosing period, which consists of 20 mg subcutaneous doses at weeks 0, 1, and 2. Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA.2,4
and I never see the needle.
Ananda: wife, mom, registered nurse, KESIMPTA patient†
Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA.
†Actual KESIMPTA patient who was compensated for their time. Individual results may vary.
What does the SC delivery difference mean for your RMS patients?
The Sensoready Pen can be administered at home or anywhere2‡
A preloaded device, ranked as easy-to-grip with audible and visual cues to help the
patient complete administration.2,5§
prefer the Sensoready Pen
attributes based on a survey5§
prefer the Sensoready Pen
attributes based on a survey5§
Meet the KESIMPTA
Sensoready Pen
See how patients learn to administer KESIMPTA with the Sensoready Pen
Take a different approach to RMS.
Make KESIMPTA your 1st choice treatment today!
‡KESIMPTA Sensoready pens must be refrigerated at 2°C to 8°C (36°F to 46°F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30°C (86°F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days.
§Based on a survey of multiple sclerosis (MS) nurses (N=50) and patients (N=80) in the US, Germany, France, and Italy. Participants were asked to compare attributes of the KESIMPTA Sensoready autoinjector pen with those of other DMT autoinjectors, some of which are not available in the US. The Sensoready Pen was not injected during the survey nor were all devices compared against each other by participants. A total of 17 attributes were assessed, with "easy to perform self-injection with the pen," "ease of preparation and set-up," and "ease of training patient in use" among those most preferred.5
have to rearrange my routine for my treatment.
Kristin: mom, real estate agent, KESIMPTA patient†
†Actual KESIMPTA patient who was compensated for their time. Individual results may vary.
KESIMPTA dosing schedule
How to discuss dosing with your patients2
To help patients understand dosing with KESIMPTA, share the instructions below:
Pick a day and start with 1 dose a week for the first 3 weeks. Skip the 4th week.
Take your first monthly maintenance dose on the
5th week.
Continue taking KESIMPTA once a month.
Dosing regimen
Initial dosing of 20 mg by subcutaneous injection at weeks 0, 1, and 2, followed by subsequent dosing of 20 mg by subcutaneous injection once monthly starting at week 4. After initial dosing, KESIMPTA is administered once monthly.2
Tracking tip
To keep it simple, tell patients to try to take KESIMPTA on the same date every month.
Example: If your first monthly dose is on April 15, take your next dose on May 15.
There's also a Quick Tips brochure available for you to download and share with your patients.
There's also a Quick Tips brochure available for you to download and share with your patients.
DOWNLOAD BROCHURE
Additional dosing information2
First Dose
The first injection should be performed under the guidance of a health care professional.
Missed Doses
Administer as soon as possible without waiting until the next scheduled dose; subsequent doses should be administered at the recommended intervals.
-
The use of premedication is not required
-
Prior to initiating KESIMPTA, perform hepatitis B virus (HBV) screening, test for quantitative serum immunoglobulins, and vaccinate (at least 4 weeks prior for live or live-attenuated vaccines and at least 2 weeks prior for inactivated vaccines)
temperature during shipping.
Maggie: wife, mom, returning college student,
KESIMPTA patient†
Please see full KESIMPTA package insert for complete instructions for storage and handling.
†Actual KESIMPTA patient who was compensated for their time. Individual results may vary.
Start your patients right away
Life with RMS is complicated enough, starting treatment shouldn't be
SCREEN
Screen your patient for HBV
and
test their Ig levels2
SHOW
Demonstrate KESIMPTA
administration using the
Sensoready Demo Pen
START
Start today with samples∥ and
submit 1-page Start Form
∥Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.
Administration details for your patients and your office
How KESIMPTA is administered
Your patients can administer KESIMPTA with the Sensoready Pen at home or anywhere with these steps. These are not the complete instructions for using KESIMPTA. Please see full Instructions For Use.2
Patients should take the Sensoready Pen out of the fridge 15-30 minutes before injection.
After a thorough hand wash, they clean their preferred injection site with an alcohol wipe.
Patients then apply the pen to the site at a 90º angle and press down. A click lets them know it's working. When they hear the second click, administration is almost complete. They can also check the green indicator to confirm a full dose.
For more information, download the Quick Tips for Use brochure for patients
For more information, download the Quick Tips for Use brochure for patients
DOWNLOAD BROCHURE
How does KESIMPTA administration differ from another B-cell therapy?
B-cell therapy administration times1,6
KESIMPTA is administered once a month subcutaneously. Ocrevus is dosed twice yearly via infusion.
*As per stability technical specification data, when the patient is ready to inject, it typically takes less than 1 minute a month to administer. Once-monthly dosing begins after the initial dosing period, which consists of 20 mg subcutaneous doses at weeks 0, 1, and 2. Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA.2,4
¶See Ocrevus Prescribing Information for complete dosing and administration instructions.
Read more about Kristin's experience with KESIMPTA
Download her KESIMPTA story
Start patients on KESIMPTA today
DOWNLOAD START FORM
Submit a Start Form by fax or online at CoverMyMeds®
VISIT COVERMYMEDS®MOA=mechanism of action; RMS=relapsing multiple sclerosis; SC=subcutaneous.
#Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.
References: 1. Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized-CD20 mice following subcutaneous or intravenous administration. P2.2-052. Poster presented at: 71st American Academy of Neurology Annual Meeting; May 4-10, 2019; Philadelphia, PA. 2. Kesimpta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 3. National Multiple Sclerosis Society. Medications. Accessed February 10, 2022. https://www.nationalmssociety.org/Treating-MS/Medications 4. Data on file. Injection time. Novartis Pharmaceuticals Corp; East Hanover, NJ. June 2020. 5. Ross AP, Besser C, Stoneman S, Gaunt H, Barker N. Patient and nurse preferences for the Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a multicenter survey. P210. Poster presented at: ACTRIMS Forum; February 25-27, 2021; Virtual. 6. Ocrevus [package insert]. San Francisco, CA: Genentech, Inc; 2021.